1572-06-1

Basic information

• Product Name: 2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE
• Synonyms: ASISCHEM D50991;AKOS BB-7922;2-(4-METHYLPHENYL)-1H-BENZIMIDAZOL-5-AMINE;2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE
• CAS NO: 1572-06-1
• Molecular Formula: C₁₄H₁₃N₃
• Molecular Weight: 223.27
• Mol File: 1572-06-1.mol

Chemical Properties

• Boiling Point: 475.9±47.0 °C(Predicted)
• Appearance: /
• Density: 1.247±0.06 g/cm3(Predicted)
• PKA: 10.90±0.10(Predicted)
• CAS DataBase Reference: 2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE(1572-06-1)
• EPA Substance Registry System: 2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE(1572-06-1)

Safety Data

• Hazardous Substances Data: 1572-06-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE is used as a building block for the synthesis of pharmaceuticals due to its unique structure and potential biological activities. It serves as an intermediate in the development of new drugs, contributing to the creation of novel therapeutic agents.
Used in Research Applications:
In the research field, 2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE is employed as a research tool for studying various biological processes and mechanisms. Its use aids in understanding the compound's interactions with biological systems, which can lead to advancements in medicinal chemistry and drug discovery.
Used in Organic Compounds Synthesis:
2-P-TOLYL-1H-BENZOIMIDAZOL-5-YLAMINE is also used as an intermediate in the synthesis of other organic compounds, expanding its applications beyond pharmaceuticals to various chemical industries that require specific organic building blocks for their products.

Upstream product

• 99-94-5 p-Toluic acid 
• 1571-90-0 2-(4-methyl-phenyl)-5-nitro-1H-benzimidazole 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 104-87-0 4-methyl-benzaldehyde 
• 1571-90-0 2-(4-methylphenyl)-6-nitro-1H-benzo[d]imidazole 

Downstream Products

• 1329517-00-1 2-chloro-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide 
• 1329517-01-2 3-chloro-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)propanamide 
• 1329517-04-5 2-(4-ethylpiperazin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide 
• 1329517-07-8 2-(4-methylpiperazin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide 
• 1329517-09-0 2-morpholino-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide 
• 1329517-10-3 2-(piperidin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide 
• 1329517-13-6 3-(4-ethylpiperazin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)propanamide 
• 1329517-16-9 3-(4-methylpiperazin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)propanamide 
• 1329517-18-1 3-(piperidin-1-yl)-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)propanamide 
• 1593834-46-8 N-(2-p-tolyl-1H-benzo[d]imidazol-6-yl)quinolin-4-amine 

Relevant articles and documents

Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase

Herein, we have carried out a structural optimization campaign to discover the novel anti-tumor agents with our previously screened YQY-26 as the hit compound. A library of thirty-seven 6-amide-2-aryl benzoxazole/benzimidazole derivatives has been designe

Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors

Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. In this work, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives were designed and identified as potent inhibitors of VEGFR-2 (

Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 are important targets for the treatment of cancers. In this study, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinazolin-4- amine derivatives were designed and identified as dual c-Met and VEGFR-2 inhibitors. Among these compounds bearing quinazoline and benzimidazole fragments, compound 7j exhibited the most potent inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05 μM and 0.02 μM, respectively. It also showed the highest anticancer activity against the tested cancer cell lines with IC50 of 1.5 μM against MCF-7 and 8.7 μM against Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of c-Met and VEGFR-2, which demonstrates that compound 7j is a potential agent for cancer therapy deserving further researching.

Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors

Multi-target EGFR, VEGFR-2 and PDGFR inhibitors are highly useful anticancer agents with improved therapeutic efficacies. In this work, we used two virtual screening methods, support vector machines (SVM) and molecular docking, to identify a novel series